Archives to Collect Info on Radiation Exposure Worldwide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

SPOKANE, Wash-A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

SPOKANE, Wash—A new organization is collecting health histories from people exposed to radiation from nuclear weapons production worldwide, to provide an international source of in-formation.

The Radiation Health Effects Archives, located on the campus of Gonzaga University, will continue and expand the collection of the Hanford Health Information Archives, founded last year to collect information about the experiences of people who lived in the region around the Hanford, Washington, nuclear facility between 1944 and 1972. These individuals are sometimes referred to as “Hanford downwinders.”

The Hanford-exposure area includes Eastern Washington, northeastern Oregon, and much of Idaho, plus areas along the Columbia River downstream from Hanford. The facility’s airborne emissions were also carried by the wind into parts of Montana and Canada.

The Archives have processed more than 400 donations with information from more than 1,100 downwinders. People have donated medical records, oral histories, journals, yearbooks, photographs, and other items that help describe their lifestyles and diets, as well as their health, from the mid-1940s to the present.

The data are available online at http://www.foley.gonzaga.edu/hhiahome.html. Comments and questions can be sent via e-mail to hhia@foley.gonzaga.edu.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content